Trial · NCT04517851
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
NCT04517851, Phase 2, Active not recruiting, M.D. Anderson Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis. Trials, record NCT04517851. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04517851
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
- NCT number
- NCT04517851
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
- Interventions
- Elotuzumab, Questionnaire Administration
- First posted
- 2020-08-18
- Last updated
- 2026-06-11
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response (OR) | Up to completion of cycle 36 (1 cycle is 28 days) | OR is defined as CR (complete response) +PR (partial response) + CI (clinical improvement), where CI includes clinical improvements in anemia, splenomegaly and/or symptoms. Will estimate the OR rate, along with the exact 95% confidence interval. |
| Secondary | Incidence of adverse events | Up to 30 days post-treatment | The method of Thall, Simon and Estey will be used to monitor for safety. The severity of the toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 whenever possible. Will follow standard reporting guidelines for adverse events. Safety data will be summarized by category, severity and frequency. |
| Secondary | Duration of response | Up to 5 years | The Kaplan-Meier method will be used to estimate the duration of response where median and 95% confidence interval will be reported. |
| Secondary | Time to next treatment | Up to 5 years | The Kaplan-Meier method will be used to estimate the time to next treatment where median and 95% confidence interval will be reported. |
| Secondary | Rates of complete response | Up to 5 years | |
| Secondary | Rates of partial response | Up to 5 years | |
| Secondary | Rates of clinical improvement | Up to 5 years | |
| Secondary | Platelet response rate | Up to 5 years | |
| Secondary | Changes in bone marrow fibrosis grade | Baseline up to 5 years | Will be assessed according to European classification. |
| Other | Biomarker analysis | Up to 5 years | Fisher's exact test will be used to assess the associations between biomarker expression (high versus low) and outcomes. Wilcoxon singed rank test will be applied to assess the change of biomarkers from baseline. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04517851
GET https://conductscience.org/api/trials/v1/NCT04517851/registered